Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

@article{Eichhorn2008Phosphatidylinositol3H,
  title={Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.},
  author={Pieter Johan Adam Eichhorn and Mag{\"u}i Gili and Maurizio Scaltriti and Violeta Serra and Marta Guzm{\'a}n and Wouter Nijkamp and Roderick L. Beijersbergen and Vanesa Valero and Joan Seoane and Ren{\'e} Bernards and Jos{\'e} Baselga},
  journal={Cancer research},
  year={2008},
  volume={68 22},
  pages={
          9221-30
        }
}
Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 271 CITATIONS, ESTIMATED 51% COVERAGE

Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.

  • Critical reviews in oncology/hematology
  • 2012
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.

  • Critical reviews in oncology/hematology
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2009
2019

CITATION STATISTICS

  • 19 Highly Influenced Citations

  • Averaged 15 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES